President Trump recently signed a pair of bills into law aimed at increasing transparency with regard to drug prices in the United States. The Patient Right to Know Drug Prices Act (S. 2554) and the Know the Lowest Price Act (S. 2553) prohibit so-called "gag clauses," which prevent pharmacists from telling customers if they could save money by buying prescription drugs out-of-pocket rather than using their health insurance. S. 2554 applies to private health plans, while S. 2553 targets Medicare Part D and Medicare Advantage plans.
ASCO in Action regularly provides the latest news and analysis related to cancer policy news; see the following online articles. These updates provide snapshots of ASCO’s ongoing advocacy efforts, as well as opportunities for ASCO members and guests to take action on critical issues affecting the cancer community.
To sign up for advocacy alerts, log in to ASCO.org with your ASCO member or guest account, and visit the subscription center available under your account profile.
More than 100 ASCO volunteers from across the country came to Capitol Hill on September 25-26 for the 2018 ASCO Advocacy Summit, where they urged Congress to act on major policy priorities to support cancer research and ensure access to high-quality care for the millions of people in the United States with cancer.
ASCO applauds Congress for passing a $2 billion increase in funding for the National Institutes of Health (NIH), which will bring NIH's budget to a total of $39.1 billion and the National Cancer Institute's to a total of $6.147 billion.
The American Society of Clinical Oncology presented Representative Kevin Yoder (KS-03) with the 2018 Congressional Leadership Award today. Each year, ASCO presents this Award to a Member of Congress who has continuously supported legislation that promotes an improved practice environment for the oncology community and improves the quality of care for cancer patients
More than 100 oncology care providers from across the United States are heading to Capitol Hill September 25 – 26 to participate in the 2018 ASCO Advocacy Summit. Advocates will meet with Members of Congress and their staff to educate them on critical issues affecting individuals with cancer and their providers, and to encourage lawmakers to support cancer policies that will ensure access to high-quality, high-value cancer care.
Senator John McCain will lie in state in the U.S. Capitol Building today. The following ASCO statement pays tribute to his life-long service to our country.
The American Society of Clinical Oncology (ASCO) warns that Medicaid work requirements may hinder patients’ access to essential cancer care and reduce the already limited time physicians are able to spend with their patients. In a new position statement released today, ASCO also recommends that federal and state policymakers take specific steps to ensure that new Medicaid requirements will not harm patients with cancer.
ASCO submitted a statement to the U.S. House of Representatives Energy and Commerce Committee in conjunction with a subcommittee hearing on implementation of the Merit-Based Incentive Payment System (MIPS) under the Medicare Access and CHIP Reauthorization Act (MACRA).
On July 25, the U.S. House Energy and Commerce Committee held a hearing during which Food and Drug Administration (FDA) Commissioner Scott Gottlieb, MD, Director of the National Cancer Institute (NCI) Norman Sharpless, MD, and Director of National Institutes of Health Francis Collins, MD, PhD, provided updates on how their respective agencies have been implementing the 21st Century Cures legislation.
"I Live to Conquer Cancer" is a new national outreach and awareness initiative that builds on ASCO’s continued advocacy activities in support of the National Institutes of Health (NIH) and the National Cancer Institute (NCI), and aims to underscore the critical importance of federally funded cancer research.
ASCO submitted comments to U.S. House of Representatives Energy and Commerce Committee leadership in conjunction with a subcommittee hearing on the 340B Drug Pricing Program, “Opportunities to Improve the 340B Drug Pricing Program.” In writing to Committee leadership, ASCO President Monica M. Bertagnolli, MD, FACS, FASCO, underscored ASCO’s appreciation for the committee’s continued efforts “to ensure the program addresses the needs of underserved patients—particularly their ability to access cancer care.”
The Senate Appropriations Committee approved a $2 billion funding increase to the National Institutes of Health (NIH) as part of its Fiscal Year (FY) 2019 Department of Labor, Health and Human Services (HHS), Education funding bill.
ASCO has launched a new ACT Network site that makes it easier-than-ever to advocate on behalf of the oncology community. As the online advocacy hub for ASCO advocates, the new ACT Network offers enhanced features that allow advocates to quickly and easily engage their lawmakers on key policy issues.
Right-to-try is the latest topic addressed in the ASCO in Action podcast series. ASCO CEO Dr. Clifford Hudis recently interviewed ASCO Senior Vice President and Chief Medical Officer Dr. Richard Schilsky to examine RTT legislation—now enacted as federal law—and discuss the Food and Drug Administration’s (FDA) expanded access program.
On June 6, 2018, the One Voice Against Cancer Coalition (OVAC) will hold an “Online Day of Action” to advocate for increased funding for the National Institutes of Health (NIH) and the National Cancer Institute (NCI).